To our knowledge, this is the first population-based observational study using routinely collected administrative data from clinical practice to investigate the cardiovascular and cerebrovascular risk associated with exposure to LDX. Results of the current study suggest that there is little to no increased risk of cardiovascular and cerebrovascular events among patients treated with LDX compared with patients previously treated with other ADHD medications.
Having a VB-affected pregnancy ending in a delivery was not associated with an increased women’s risk of cancer in comparison with having a VB-unaffected pregnancy ending in a delivery, termination or miscarriage.
The birth of a child affected by TAB in utero was associated with a greater risk of CP, but not epilepsy or ADHD.
Women’s risks of diabetes types 1 and 2 and multiple cardiovascular outcomes were increased on the relative scale following childbirths affected by VB within 20 gestational weeks when compared with VB-unaffected childbirths and terminations, but not …